Therapeutic impact of epidermal growth factor receptor tyrosine kinase inhibitor with various treatment combinations for advanced lung adenocarcinoma

• Published in: World journal of surgical oncology Vol. 21; no. 1; p. 326
• Main Authors: Chen, Ying-Yi, Lin, Kuan-Hsun, Kuo, Yen-Shou, Tsai, Yuan-Ming, Huang, Hsu-Kai, Huang, Tsai-Wang
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 13.10.2023; BioMed Central; BMC
• Subjects: Adenocarcinoma; Adenocarcinoma - drug therapy; Adenocarcinoma - genetics; Adenocarcinoma of Lung - drug therapy; Adenocarcinoma of Lung - genetics; Biopsy; Bronchoscopy; Cancer; Cancer therapies; Care and treatment; Chemotherapy; Clinical trials; Cohort analysis; Development and progression; Enzyme inhibitors; Epidermal growth factor; Epidermal growth factor receptor; Epidermal growth factor receptors; ErbB Receptors - genetics; Gender; Gene mutations; Genetic aspects; Growth factors; Health aspects; Health services; Humans; Kinases; Lung adenocarcinoma; Lung cancer; Lung Neoplasms - drug therapy; Lung Neoplasms - genetics; Lymphatic system; Medical prognosis; Medical records; Metastasis; Mutation; Patient outcomes; Patients; Protein Kinase Inhibitors - therapeutic use; Protein-tyrosine kinase receptors; Radiation therapy; Receptors; Regression analysis; Retrospective Studies; Salvage surgery; Statistical analysis; Surgery; Survival; Tomography; Tyrosine; Tyrosine kinase inhibitor; Tyrosine Kinase Inhibitors; Ultrasonic imaging; China; Asia; Europe; Lung adenocarcinoma; Salvage surgery; Tyrosine kinase inhibitor; Epidermal growth factor receptor
• ISSN: 1477-7819; 1477-7819
• DOI: 10.1186/s12957-023-03203-6

Tyrosine kinase inhibitors (TKIs) are the primary therapeutic option for patients with advanced-stage epidermal growth factor receptor-mutant (EGFR-m) lung adenocarcinoma. However, the role of EGFR-TKIs in advanced-stage lung cancer is uncertain regardless of therapeutic methods. This study investigated the outcome of the impact of epidermal growth factor receptor (EGFR)-TKI in patients with advanced lung adenocarcinoma treated with various therapeutic strategies. This retrospective analysis used cancer registry data from 1159 patients with lung cancer treated between January 2015 and December 2017 at Tri-Service General Hospital. Only patients with lung adenocarcinoma stages 3B and four were selected for the study. All lung adenocarcinoma patients with ever TKI treatment had an EGFR mutation. Three-hundred sixty-two patients with advanced lung adenocarcinoma with complete medical records were enrolled. According to personalized therapeutic processes, they were divided into nine groups: only TKI treatment, only chemotherapy (CT), TKI with lung cancer salvage surgery, TKI with CT, TKI with radiotherapy (RT), CT with lung cancer salvage surgery, CT with RT, TKI with CT, and lung cancer salvage surgery. A multivariate Cox regression analysis showed TKI with lung cancer salvage surgery (HR: 4.675, p = 0.005) is the only good prognostic treatment. The poor predictors for overall survival were only CT (HR: 0.336, p = 0.048) and TKI with CT (HR: 0.359, p = 0.023). Kaplan-Meier survival analysis showed a statistical significance in an average overall survival (OS) of ever TKI treatment and never TKI treatment (33.24 vs. 17.64 months, p < 0.001). Furthermore, TKI usage duration was statistically increased in TKI with lung cancer salvage surgery (40.4 ± 20.7 vs 14.96 ± 13.13 months, p < 0.001). The survival rate (p = 0.033) and OS (p < 0.001) in lung cancer salvage surgery were statistically better than the group of TKI without surgery. The best therapeutic strategy for advanced lung adenocarcinoma is TKI with lung cancer salvage surgery, according to significantly longer OS and better survival. It also prolonged TKI usage. Mutated EGFR lung adenocarcinoma patients with ever TKI treatment had significantly better survival than with other treatments. Regardless of the combination of other treatments, EGFR mutation with TKI therapy is recommended as a positive prognostic factor for patients with lung adenocarcinoma.